|
Septicemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion</b> We uncovered an association between IL-10 1082 gene variation and sepsis in VLBW infants but did not identify associations between neonatal sepsis and TNF-α 308 or IL-6 gene variation.
|
27960200 |
2017 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> UTI effectively protects TJs and helps to attenuate the permeability of pulmonary capillary endothelial cells during sepsis through inhibiting NF-κB and MAPKs signal pathways and TNF-α expression.
|
30150933 |
2018 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sepsis induces the activation of complement factor via 3 pathways and the release of inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1beta (IL-1β), resulting in a systemic inflammatory response.
|
28525674 |
2017 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sepsis is more common in the elderly.TNF⍺ is recognized as an important mediator in sepsis and Toll-like receptors (TLRs) play an important role in initiating signaling cascades to produce TNF⍺.
|
30402800 |
2019 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sepsis induced a generalized up-regulation of both human and murine plasma cytokines (TNFα, IL-6, IL-10, IL-8/KC, MCP-1); it was additionally aggravated in P-DIE vs. P-SUR.
|
31297113 |
2019 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor alpha (TNF-alpha) has well-described effects on lipid metabolism in the context of acute inflammation, as in sepsis.
|
10878750 |
2000 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha (TNF-alpha) is a well-documented central inflammatory mediator in sepsis.
|
12906716 |
2003 |
|
Septicemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor alpha -- 308 polymorphism associated with increased sepsis mortality in ventilated very low birth weight infants.
|
15131465 |
2004 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor alpha as a central mediator of the inflammation cascade is correlated to sepsis outcome.
|
15187748 |
2004 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha (TNF-alpha) is thought to play a major role in systemic inflammation associated with sepsis.
|
18848768 |
2009 |
|
Septicemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor (TNF)-α variant is closely linked to sepsis syndrome and mortality after severe trauma.
|
26117649 |
2015 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)-α is a pleiotropic cytokine with intense pro-inflammatory and immunomodulatory properties, and anti-TNF-α biologics are effective therapies for various inflammatory diseases such as inflammatory bowel disease (IBD) and sepsis.
|
27879679 |
2016 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha (TNF-α) is a pivotal mediator that triggers inflammatory process, oxidative stress, and multiple organ injury in sepsis.
|
28459157 |
2017 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumour Necrosis Factor-alpha and Nuclear Factor-kappa B Gene Variants in Sepsis.
|
28840846 |
2018 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)-α activates a diverse array of signaling pathways in vascular endothelial cells (ECs), leading to the inflammatory phenotype that contributes to the vascular dysfunction and neutrophil emigration in patients with sepsis.
|
29493888 |
2018 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) is recognized as a central mediator of sepsis, septic shock, and multiple organ failure.
|
8832971 |
1997 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha (TNF-alpha) plays a central role in the pathophysiology of sepsis.
|
8843235 |
1996 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A genomic polymorphism within the TNF locus is associated with increased TNF-alpha levels and high mortality in severe trauma and sepsis.
|
14500138 |
2003 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
A number of pre-clinical studies have shown an auto amplification of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, and IL-6 in the first few hours after sepsis induction, also increased blood-brain barrier permeability, elevated levels of matrix metalloproteinases, increased levels of damage-associated molecular patterns were demonstrated.
|
29687346 |
2019 |
|
Septicemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A recent meta-analysis demonstrated that the tumor necrosis factor-α -308 A allele is associated with higher sepsis risk in adult cohorts.
|
21317641 |
2011 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A review of past and future clinical strategies for altering TNF activity during sepsis is also provided.
|
7850574 |
1995 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Administration of fasudil led to reductions in polymorphonuclear neutrophil counts, and the protein concentrations of tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6 in the bronchoalveolar lavage fluid of rats with sepsis‑induced ALI.
|
30221694 |
2018 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
After excluding the compounds which are previously known to intervene sepsis or which show cytotoxicity to macrophages, the compounds which show dose-dependency in inhibiting the release of IL-6 and TNF-α by the OMV-stimulated macrophages in vitro and which reduce OMV-induced SIRS in vivo are selected.
|
29683274 |
2018 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although KEGG showed inflammatory bowel disease in the E. coli group, the KEGG pathway analysis showed that these DEGs were mainly involved in the tumor necrosis factor signaling pathway, fructose metabolism, and mannose metabolism in both <i>S. aureus</i>- and <i>E. coli</i>-induced sepsis.
|
31093495 |
2019 |
|
Septicemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-TNF strategies based on monoclonal antibodies or F(ab')₂ fragments have been used in sepsis with contradictory results.
|
23548047 |
2013 |